Sino Biopharmaceutical Limited (SBMFF)
Sino Biopharmaceutical Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Hong Kong, HK. The stock last traded at $0.61, up 0.00% on the session, giving a market capitalisation of $10.87B. On trailing twelve-month figures it carries a trailing P/E of 32.49, a net margin of 7.4%. Its beta of 0.60 implies it has historically moved less than the broad market.
Sino Biopharmaceutical Limited operates as a leading investment holding entity and a research and development-focused pharmaceutical conglomerate, primarily active within the People's Republic of China. Its business activities are organized into three primary divisions: Modernised Chinese Medicines and Chemical Medicines, Investment initiatives, and other miscellaneous operations. The company offers a comprehensive range of pharmaceutical products spanning various therapeutic areas. This portfolio includes oncology medications like Qingkeshu, Anxian, Yinishu, Genike, Anyue capsules, and Leweixin injections; cardio-cerebral vascular drugs such as Kaina and Anrixin tablets; and treatments for hepatitis, including Tianqingganmei injections and Tianqingganping enteric capsules. It also produces orthopedic medicines like Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medications; parenteral nutritious solutions such as Xinhaineng and Fenghaina injections; and other pharmaceuticals, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. Furthermore, its advanced drug offerings feature specific products like Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. Beyond its core pharmaceutical manufacturing, Sino Biopharmaceutical engages in a diverse set of related healthcare and commercial ventures. These encompass managing properties; the retail and distribution of pharmaceutical goods; providing optometry services and selling ophthalmic products; operating hospitals; and offering medical management, health information consultancy, and bio-tech transfer and advisory services. The company also manufactures and markets health food, performs orthopedic outpatient and surgical procedures, develops medical and health technologies, trades optical eyewear, and is involved in the research, development, and sale of medical devices and active pharmaceutical ingredients. The company was established in 2000 and has its corporate headquarters situated in Wan Chai, Hong Kong.
Sino Biopharmaceutical Limited is most often compared with the following Healthcare names: